Diabetes Drug Makers Seek $686,002 In Fees, Costs After Preemption Win In MDL
SAN DIEGO — Sixteen days after a California federal judge granted summary judgment in the incretin mimetic multidistrict litigation on the basis of preemption, experts and causation, four diabetes drug manufacturers...To view the full article, register now.
Already a subscriber? Click here to view full article